http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2010311397-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_449ffef3a83ab4433b7ca72a5d9f5478
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_47a451cdcf31d1bc9b6b7fbcbd428d31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ec0024795f45a646ef64b3664ab8a26d
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
filingDate 2010-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b045110f75b27c0d2214cd83f77b9dd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdd57231a8b11b845204d32a1699acb8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b9a9fe55745a8ce7bcc47bd96ca27ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2898b0faebcf5f7191852bb947d097ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_639f796cf4b1d79a5c2a9b79ee7819f5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cba4d6103ebf664c23040d901751e016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d3652668415debaa7efadc67435d034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dfa3ae3258fc211ff613d9727758506d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad00097666dcacea7c3e9d8762294636
publicationDate 2012-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2010311397-A1
titleOfInvention Circulating miRNAs as non-invasive markers for diagnosis and staging in prostate cancer
abstract The present invention relates to a method for staging prostate cancer in a subject suffering from prostate cancer, said method comprises (a) determining the amount of at least one miRNA selected from the group consisting of miRNA-375, miRNA-141, miRNA-200b, miRNA-516a-3p and miRNA9*, or the amount of a precursor molecule in a sample from said patient and (b) comparing the, thus, determined amount with a reference amount. Moreover, the present invention is concerned with a method for identifying a subject susceptible to prostate cancer therapy and to a method for diagnosing prostate cancer. Further envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention.
priorityDate 2009-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419547014
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID719444
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP33619
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID408211
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID147605
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID147605
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414859283
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9999
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ6DT45
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6547
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID354
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP07288

Total number of triples: 36.